Article
Endocrinology & Metabolism
Muthiah Vaduganathan, Silvio E. Inzucchi, Naveed Sattar, David H. Fitchett, Anne Pernille Ofstad, Martina Brueckmann, Jyothis T. George, Subodh Verma, Michaela Mattheus, Christoph Wanner, Bernard Zinman, Javed Butler
Summary: Empagliflozin delays insulin initiation and reduces the need for substantial increases in insulin dose in patients with type 2 diabetes and cardiovascular disease, while also facilitating sustained reductions in insulin requirements over time.
DIABETES OBESITY & METABOLISM
(2021)
Review
Pharmacology & Pharmacy
Betul R. Erdogan, Guiming Liu, Ebru Arioglu-Inan, Martin C. Michel
Summary: This study reviewed the efficacy of classic medications for the treatment of lower urinary tract dysfunction in diabetic patients and animals. The findings suggest that these medications have comparable efficacy in patients and/or animals with and without diabetes. The effects of antidiabetic medications on lower urinary tract function and emerging medications targeting diabetes-associated dysfunction are also discussed. Nonpharmacological interventions show promising results in preclinical studies. However, further experimental and clinical studies are needed to develop effective treatments for diabetic uropathy.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Rainer U. Pliquett, Linda Golle, Andreas Wienke, Matthias Girndt
Summary: Real-world data suggest that incretin mimetic therapy is not widely used in type-2 diabetics with atherosclerotic vascular disease. A study on type-2 diabetics undergoing myocardial revascularization found that incretin mimetics were associated with lower prevalence, while hypoglycemic events were more frequent in insulin-treated patients.
Letter
Cardiac & Cardiovascular Systems
Bo Liang, Ning Gu
Summary: The 2022 AHA/ACC/HFSA guideline for heart failure management recommends the use of sodium-glucose co-transporter-2 inhibitors in patients with heart failure and type 2 diabetes to manage hyperglycemia and reduce heart failure-related morbidity and mortality. However, it should be noted that this recommendation is based on specific trials and does not include recently published studies.
CARDIOVASCULAR DIABETOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Louise E. Bechmann, Frida Emanuelsson, Borge G. Nordestgaard, Marianne Benn
Summary: A functional genetic variant in SLC5A2, mimicking SGLT2-inhibition, was associated with a lower risk of heart failure, myocardial infarction, ischaemic heart disease, and all-cause mortality. However, the effects were minimally mediated through lower plasma glucose.
CARDIOVASCULAR RESEARCH
(2023)
Letter
Surgery
Antonia-Therese Kietaibl, Peter Fasching, Karl Glaser, Alexander H. Petter-Puchner
Summary: This article provides a brief overview of literature regarding sodium-glucose co-transporter 2 inhibitor-induced ketoacidosis in the surgical and perioperative context.
BRITISH JOURNAL OF SURGERY
(2021)
Review
Endocrinology & Metabolism
Kamlesh Khunti, Serge Jabbour, Xavier Cos, Sunder Mudaliar, Christian Mende, Marc Bonaca, Paola Fioretto
Summary: Recent studies have shown the benefits of SGLT-2 inhibitors in T2D patients, particularly in cardiovascular and renal protection, however uptake rates remain low due to safety concerns, cost, and lack of understanding among clinicians. Modifying guidelines and increasing education for both patients and clinicians may help increase uptake of these drugs.
DIABETES OBESITY & METABOLISM
(2022)
Review
Cell Biology
Habib Yaribeygi, Mina Maleki, Fatemeh Nasimi, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar
Summary: SGLT2 inhibitors may enhance hematopoiesis and stimulate erythropoiesis in diabetic patients, potentially providing additional benefits.
JOURNAL OF CELLULAR PHYSIOLOGY
(2022)
Review
Cell Biology
Tanawat Attachaipanich, Siriporn C. Chattipakorn, Nipon Chattipakorn
Summary: This review summarizes the current available evidence regarding the potential benefits of SGLT-2 inhibitors against cardiac arrhythmias, ranging from basic research to clinical reports. It comprehensively examines the effects of SGLT-2 inhibitors on cardiac action potential, cellular ion currents, calcium ion homeostasis, and cardiac mitochondrial function, as well as the association with arrhythmias such as atrial fibrillation and ventricular arrhythmias.
JOURNAL OF CELLULAR PHYSIOLOGY
(2022)
Review
Pharmacology & Pharmacy
Xiaoling Li, Benedikt Preckel, Jeroen Hermanides, Markus W. Hollmann, Coert J. Zuurbier, Nina C. Weber
Summary: SGLT-2is improve cardiovascular outcomes by directly affecting endothelial function through various pathways. These effects include reducing oxidative stress and inflammatory reactions, restoring vasodilation, and regulating angiogenesis.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Qingchun Zeng, Qing Zhou, Weitao Liu, Yutong Wang, Xingbo Xu, Dingli Xu
Summary: Heart failure is a common complication of various heart diseases, and SGLT2 inhibitors have shown beneficial effects in reducing hospitalization and mortality rates in HF patients through multiple mechanisms beyond lowering glucose levels.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Evangelia S. Makri, Antonis Goulas, Stergios A. Polyzos
Summary: NAFLD is a common liver disease with potentially severe consequences, and pharmacological therapy is still lacking. SGLT-2 inhibitors show promising potential for treating NAFLD, especially in improving liver function.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Joao Pedro Ferreira, Joana Pimenta, Brenda Moura, Carlos Aguiar, Fatima Franco
Summary: This article reviews the potential utility of SGLT2 inhibitors in patients hospitalized for acute heart failure, highlighting that besides SGLT2 inhibitors, other drugs have failed to improve the prognosis of AHF patients.
Article
Endocrinology & Metabolism
Seung Eun Lee, Hyewon Nam, Han Seok Choi, Hoseob Kim, Dae-Sung Kyoung, Kyoung-Ah Kim
Summary: Comparison between SGLT-2i and TZD in T2DM patients showed comparable risk of stroke, but a significant decrease in hospitalization for heart failure in the SGLT-2i-treated group.
DIABETES & METABOLISM JOURNAL
(2022)
Review
Endocrinology & Metabolism
Fang-Hong Shi, Hao Li, Long Shen, Li Xu, Heng Ge, Zhi-Chun Gu, Hou-Wen Lin, Jun Pu
Summary: Treatment with SGLT2 inhibitors can significantly improve left ventricular function in patients with or without diabetes, especially those with heart failure or undergoing empagliflozin treatment. LV mass, ejection fractions, volumes, and diastolic function were all significantly improved in patients treated with SGLT2 inhibitors. Subgroup analysis further confirmed the improvement of LV function mainly in patients with heart failure or those receiving empagliflozin treatment.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Letter
Endocrinology & Metabolism
Awadhesh Kumar Singh, Ritu Singh, Anoop Misra
JOURNAL OF DIABETES
(2021)
Article
Endocrinology & Metabolism
Awadhesh Kumar Singh, Sanjeev Ratnakar Phatak, Ritu Singh, Kingshuk Bhattacharjee, Nagendra Kumar Singh, Arvind Gupta, Arvind Sharma
Summary: According to this study, there is a decline in humoral antibody levels after six months of receiving either Covishield or Covaxin vaccines against SARS-CoV-2 in India. Covishield recipients had higher antibody levels compared to Covaxin recipients, but there was a significant decrease in antibody titers with Covishield at six months, while there was no decline with Covaxin.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2022)
Review
Endocrinology & Metabolism
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, Anoop Misra
Summary: Molnupiravir is an oral antiviral drug that has received emergency use authorization in the USA, UK, and India. Recent studies have shown that it can significantly reduce the risk of hospitalization or death in non-hospitalized COVID-19 patients. Molnupiravir is comparatively cheaper than other agents and can be an effective option for treating COVID-19, but it needs to be used within 5 days of symptom onset.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2022)
Review
Endocrinology & Metabolism
Awadhesh Kumar Singh, Ritu Singh, Anoop Misra
Summary: This study reviewed the efficacy and safety of oral semaglutide in the treatment of type 2 diabetes mellitus (T2DM) and concluded that 14 mg oral semaglutide is an effective agent. However, real-world studies of semaglutide are needed in India due to the lack of meaningful data from randomized controlled trials (RCTs) involving Indian participants.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2022)
Letter
Endocrinology & Metabolism
Awadhesh Kumar Singh
ENDOCRINE PRACTICE
(2022)
Article
Endocrinology & Metabolism
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, Anoop Misra
Summary: Insulin icodec is an advanced candidate insulin suitable for once-weekly administration. This systematic review found that insulin icodec showed better glucose control and reduced injection frequency in patients with type 2 diabetes compared to other basal insulin analogs. However, it was associated with a higher risk of hypoglycemia in patients with type 1 diabetes.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2022)
Review
Endocrinology & Metabolism
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, Anoop Misra
Summary: Finerenone, a novel non-steroidal mineralocorticoid antagonist, shows promising efficacy in improving renal outcomes and reducing mortality in patients with chronic kidney disease. However, it may increase the risk of hyperkalemia.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2022)
Review
Endocrinology & Metabolism
Mahmoud Nassar, Hazem Abosheaishaa, Awadhesh Kumar Singh, Anoop Misra, Zachary Bloomgarden
Summary: The use of metformin and GLP-1RA medications in patients with COVID-19 can significantly reduce the risk of mortality. However, the use of DPP-4i medications is associated with an increased risk of hospitalization and ICU admission.
JOURNAL OF DIABETES
(2023)
Review
Endocrinology & Metabolism
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, Anoop Misra
Summary: This systematic review and meta-analysis evaluated the efficacy of Imeglimin in patients with type 2 diabetes. The results showed that Imeglimin at a dose of 1000 mg twice daily significantly reduced HbA1c levels.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2023)
Article
Endocrinology & Metabolism
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh
Summary: This study conducted a trial-level meta-analysis and found that the combination of SGLT2i and DPP4i in the treatment of type 2 diabetes may have similar cardiovascular and renal benefits. This finding is of great significance in filling the existing knowledge gap.
ENDOCRINE PRACTICE
(2023)
Article
Endocrinology & Metabolism
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh
Summary: A recent meta-analysis found that sodium-glucose cotransporter-2 inhibitors (SGLT2i) have the potential to reduce the incidence of new-onset diabetes (NOD) in adults with prediabetes. The meta-analysis included five randomized controlled trials and found a significant reduction in NOD with SGLT2i. However, further research is needed to confirm these findings and understand the underlying mechanisms.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2023)
Review
Endocrinology & Metabolism
Kalyan Kumar Gangopadhyay, Awadhesh Kumar Singh
Summary: This study aimed to conduct a systematic review of Lobeglitazone (LGZ) and evaluate its efficacy and safety in patients with type 2 diabetes (T2D) compared to pioglitazone (PGZ). The results showed that LGZ was more effective than placebo in reducing HbA1c but similar to PGZ and sitagliptin (SITA). Weight gain with LGZ was similar to PGZ. Further research is needed to determine the advantages of LGZ over PGZ.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2023)
Article
Endocrinology & Metabolism
Subir Ray, Awadhesh Kumar Singh, Jagat Jyoti Mukherjee, Raja Ramachandran, Upal Sengupta, Anil Kumar Virmani, Arup Ratan Dutta, Surendra Kumar Sharma, Sanjay Lal Srivastava, Masood Batin
Summary: Most guidelines recommend protein restriction in adults with chronic kidney disease (CKD), but it is controversial to advise protein restriction for every person with CKD. The study aimed to reach a consensus on this topic, especially among Indian adults with CKD.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2023)
Article
Endocrinology & Metabolism
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, Shashank R. Joshi, Anoop Misra
Summary: A systematic review and meta-analysis conducted by the WHO assessed the health outcomes of non-sugar sweeteners (NSS) and reported conflicting findings. The review found that while short-term benefits were observed in RCTs, long-term harm was found in PCSs, highlighting the need for further research.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2023)